NICE recommends ixekizumab for persistent severe plaque psoriasis

Click for article

The National Institute for Health and Care Excellence (NICE), in its final draft guidance issued this week, has recommended ixekizumab, an antibody that inhibits interleukin-17A, as an option for treating adults with severe plaque psoriasis that doesn’t respond to standard therapies.

Advertisements

End of life care for infants, children and young people with life limiting conditions: summary of NICE guidance

Click for article

Click for article

Children and young people can have a wide range of life limiting conditions and may sometimes live with such conditions for many years. This guideline recommends that end of life care be managed as a long term process that begins at the time of diagnosis of a life limiting condition and entails planning for the future. Sometimes it may begin before the child’s birth. It is part of the overall care of the child or young person and runs in parallel with other active treatments for the underlying condition itself. Finally, it includes those aspects related to the care of the dying.

NICE calls for tailored care for complex, long term health conditions

Nice_logo   The number of people with many long-term health conditions is set to rise and physicians need to discuss both the benefits and any adverse effects of treatments with patients.

Aimed at healthcare professionals, GPs and physicians, a new NICE guideline (Multimorbidity: clinical assessment and management, NG56) sets out ways to put patients with complex health issues at the heart of decisions about their care, including how to decide between different medicines and treatments. It should also help clinicians to work with their patients to  deliver person centred care suited to their needs.

The news release can be read here and the full guideline is Multimorbidity: clinical assessment and management NICE guideline [NG56]

NICE recommends dropping two drugs from Cancer Drugs Fund

Click for article

Click for article

Two drugs currently provided under the Cancer Drugs Fund (CDF) should cease to be available because they are not cost effective, the National Institute for Health and Care Excellence (NICE) has concluded.

Everolimus for breast cancer (Afinitor, Novartis) and ibrutinib for mantle cell lymphoma (Imbruvica, Janssen) do not meet the grade, says NICE in draft guidance now open for consultation.Nice_logo

Suspected sepsis: summary of NICE guidance

nice_logoGuidelines include:

  • “Think sepsis” in any person with suspected infection

  • Sepsis may present with non-specific symptoms and signs and without fever

  • Have a high index of suspicion of sepsis in those who are aged <1 year or >75 years, pregnant, or immunocompromised, and those who have a device or line in situ or have had recent surgery

  • Use risk factors and any indicators of clinical concern to decide if full assessment is required

  • Offer people at high risk of sepsis broad spectrum antibiotics and intravenous fluids in hospital

National problem with NHS Athens administration

athensThere is currently a problem with logging into OpenAthens Administration accounts, which means that we are temporarily unable to help people if they have Athens queries or are having problems with their personal accounts.

This is a national problem that is being looked into as a matter of urgency and we will update people as soon as more information is available. Thank you for your patience.